報價延遲最少15分鐘:2024/12/23 22:25 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.15 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.64/-2.23
|
|
企業價值
189.47M
|
| 資產負債 |
|
每股賬面淨值
2.38
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:25 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatmentoptions. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD). |